WallStSmart

Arvinas Inc (ARVN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Arvinas Inc generates 11949% more annual revenue ($89.40M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -247.5%. ARVN earns a higher WallStSmart Score of 28/100 (F).

ARVN

Avoid

28

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 6/9Altman Z: -1.30

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARVNUndervalued (+76.3%)

Margin of Safety

+76.3%

Fair Value

$55.24

Current Price

$7.42

$47.82 discount

UndervaluedFair: $55.24Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARVN2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ARVN4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$516.17M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-57.2%2/10

ROE of -57.2% — below average capital efficiency

Revenue GrowthGrowth
-91.7%2/10

Revenue declined 91.7%

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARVN

The strongest argument for ARVN centers on Price/Book, Debt/Equity.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ARVN

The primary concerns for ARVN are EPS Growth, Market Cap, Return on Equity.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

ARVN profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

ARVN carries more volatility with a beta of 1.80 — expect wider price swings.

ARVN is growing revenue faster at -91.7% — sustainability is the question.

ARVN generates stronger free cash flow (-71M), providing more financial flexibility.

Bottom Line

ARVN scores higher overall (28/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Arvinas Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Arvinas, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of therapies to break down disease-causing proteins. The company is headquartered in New Haven, Connecticut.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?